Article

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma

2026-04-02

Abstract excerpt

<h4>PURPOSE</h4> Newly-diagnosed glioblastoma (nGBM) is a devastating tumor with median survival of only 14-18 months despite aggressive standard of care (SOC). Dendritic cell (DC) homologous antigenic double-loading provides a powerful pattern-based signal that initiates cDC1-like skewing of monocytic precursors, inducing downstream development of CD8 + memory effectors. Here we report phase I results for DOC10...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4fc50a8b-4dc5-5233-8e63-bb35d80af600
DOI: 10.64898/2026.03.28.26349013

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of GlioblastomaDOI 10.64898/2026.03.28.26349013Read

Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma PatientsSemantic proximity Read

A vaccine targeting mutant IDH1 in newly diagnosed glioma.Semantic proximity Read

Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed GlioblastomaSemantic proximity Read

COVID-19 Vaccines: Bolstering Cancer TreatmentSemantic proximity Read

Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastomaSemantic proximity Read

Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastomaSemantic proximity Read

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastomaSemantic proximity Read

Transcriptional Plasticity and Platform-Specific Immune Targetability in IDH-Wildtype GlioblastomaSemantic proximity Read

Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.Semantic proximity Read

Systemic viral vector vaccination induces brain resident memory T cells to drive anti-glioblastoma immunitySemantic proximity Read

Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanomaSemantic proximity Read

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade gliomaSemantic proximity Read